CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday.
The drug, called Elahere, is made by the biotech company ImmunoGen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors. The new findings demonstrating prolonged survival will likely lead to a final approval and broader use by physicians who treat women with ovarian cancer, experts said.
In the study, participants treated with the drug lived for a median of 16.5 months compared to just under 13 months for participants treated with standard chemotherapy. Statistically, Elahere reduced the risk of death by 33%. The drug also shrank tumors and delayed disease progression.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect